Pharmacy Times

JULY 7, 2025

Takeda will discontinue Gammagard S/D by December 2027, transitioning to the new low IgA formulation. Takeda has informed the FDA that the manufacturing of Gammagard S/D will cease in December 2027.

FDA 97

FDA Immunization Compounding Pharmacies Compounding 97

Roots Analysis

JANUARY 27, 2025

This can be attributed to the fact that encapsulation technology allows tailored release of the active compounds, enabling sustained or targeted delivery to specific sites in the body. Further, majority of the technologies in the subcutaneous biologics industry are working on encapsulation principle.

Hospitals 40

Hospitals Packaging Compounding Immunization 40

PharmTech

JULY 22, 2025

Image Credit: © wacomka - stock.adobe.com PMMI, The Association for Packaging and Processing Technologies, has announced some of the unique features being made available to attendees at Pack Expo Las Vegas, to be held from Sept. Pacteon Exhibits New Packaging Automation Solutions at Pack Expo International 2024. 29 through Oct.

Dosage 59

Dosage Packaging Compounding Vaccines 59

pharmaphorum

FEBRUARY 3, 2022

As Part of Europe’s leading Injectable conference series, we will assess innovations in drug product formulation and biologics, new technologies in device design and the use of long-release injectable compounds. The injectable drug delivery market is expected to rise at a compound annual growth rate of 12.9% Device Engineering.

Compounding 52

Compounding Packaging Vaccines 52

ISPE

SEPTEMBER 11, 2023

4 , 5 Additionally, reducing shipping limitations—such as packaging, storage, and transportation durations—helps speed up patient access in certain instances while ensuring there is no negative impact to the product’s critical quality attributes (CQAs). These new operating models can help enable and accelerate the efforts of Pharma 4.0™

Health and Personal Care Stores 52

Health and Personal Care Stores Vaccines Packaging Documentation 52

ISPE

MARCH 8, 2023

The cases covered the same types of contaminants and impurities noted in Table 1: microbial contaminants, process-related im-purities, metal contaminants, packaging-related contaminants, drug cross-contamination, and an “unknown” category encompassing other contaminants associated with the manufacturing process, including those from cell culturing.

Compounding 52

Compounding Compounding Pharmacies Packaging FDA 52